Progression Free Survival, Overall Survival, and Relapse Rate in Endometrioid Ovarian Cancer and Synchronous Endometrial-Ovarian Endometrioid Cancer (SEO-EC): Results from a Large Retrospective Analysis

Abstract

Background and Objectives: We aimed to evaluate Progression Free Survival (PFS), Overall Survival (OS), and relapse rate in women affected by endometrioid ovarian cancer and synchronous endometrial-ovarian endometrioid cancer (SEO-EC). As secondary outcome, we assessed whether systematic pelvic and para-aortic lymphadenectomy could be considered a determinant of relapse rate in this population. Materials and Methods: We performed a retrospective analysis of women with diagnosis of endometrioid ovarian cancer or SEO-EC between January 2010 to September 2020, and calculated PFS, OS and relapse rate. Results: In almost all the patients (97.6%) who underwent systematic pelvic and para-aortic lymphadenectomy, there were no lymph node metastases confirmed by histology. We did not find a significant difference (p = 0.6570) for the rate of relapse in the group of women who underwent systematic pelvic and para-aortic lymphadenectomy (4/42; 9.5%) compared with the group of women who did not undergo the same procedure (1/21; 4.8%). During a median follow-up was 23 months, both PFS and OS were excellent. Conclusions: Women affected by early-stage low-grade endometrioid cancer and SEO-EC without apparent lymph node involvement at pre-operative imaging showed a very low rate of lymph node metastasis and similar relapse rate with or without lymphadenectomy.

Radical Total Pelvic Exenteration with Concomitant Right Nephrectomy in the Management of Recurrent Endometrioid Ovarian Adenocarcinoma: A Case Report and Literature Review

“…Several studies have suggested that endometrioid carcinomas have higher rates of both 5-year overall survival (80.6%) and progression-free survival (68%) compared to other ovarian cancer subtype. Additionally, they have a lower recurrence rate, especially at lower grades [1,6]. Relapse patterns appear to further differentiate endometrioid carcinomas from serous carcinomas, with endometrioid carcinomas having a much higher proportion, at nearly 50%, recurring solely in the pelvis, while serous carcinoma relapse tends to be much more diffuse [6].…”

“…The most common form of ovarian cancer is epithelial ovarian cancer, of which the serous subtype is most common. The second most common, accounting for approximately 10% of epithelial ovarian cancers, is endometrioid carcinoma [1]. As a result of the rare nature of ovarian endometrioid carcinoma, research and understanding of this subtype, its presentation, management, and prognosis, are limited.…”

Fertility-Sparing Strategies for Early-Stage Endometrial Cancer: Stepping towards Precision Medicine Based on the Molecular Fingerprint

“…In a real world scenario, patients with endometrial cancer during reproductive age who are candidates for a fertility-sparing approach have the stage IA, G1, low-grade endometrioid subtype [13]. However, myometrial [14], adnexal [15], and lymph-vascular space invasion must be excluded before offering a fertility-sparing approach [16]. Accumulating evidence suggests that hysteroscopic resection of the tumor, followed by hormonal treatment, could be acceptable in terms of oncological and reproductive outcomes [17].…”